Bone and Joint Infection, Dactinomycin Adverse Reaction
Conditions
Keywords
bone and joint infection, adverse event, daptomycin, Eosinophilic pneumonia, CPK, rhabdomyolysis
Brief summary
the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection
Detailed description
Daptomycin is widely used in osteoarticular infections (IOA), as an alternative to vancomycin, and recommended for this use by various learned societies including the Infectious Diseases Society of America (IDSA) in 2013. Tolerance to daptomycin is generally favorable, with in particular better renal tolerance than vancomycin. However, two rare and potentially severe side effects have been described with this antibiotics: muscle toxicity and eosinophilic pneumonia.
Interventions
OTHERpatients having had BJI or PJI treated with daptomycin
patients having had BJI or PJI treated with daptomycin who developped an adverse event : eosinophilic pneumonia and/or elevation of CPK
Sponsors
Hospices Civils de Lyon
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patients who have had an osteoarticular infection, treated with daptomycin, with at least one blood test for daptomycin performed
Exclusion criteria
* Patients who objected to participating in the study * Absence of blood dosage of daptomycin
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| rate of patients having had a PJI or BJI treated by daptomycin | between 2010 and 2020 | proportion of patients treated by daptomycin |
| description of BJI/PJI | between 2010 and 2020 | type of BJI or PJI |
| description of patients | between 2010 and 2020 | comorbidites |
| description of adverse event | between 2010 and 2020 | type of adverse event |
| rate of patients having had an adverse event | between 2010 and 2020 | proportion of patients having had an adverse event under daptomycin |
| Evalutation of the adverse event due to daptomycin : dosage of daptomycine | between 2010 and 2020 | description of the use of daptomycine : dosage |
| Evalutation of the adverse event due to daptomycin : duration of daptomycine | between 2010 and 2020 | description of the use of daptomycine : duration |
| Evalutation of the adverse event due to daptomycin : daptomycine plasma clearance | between 2010 and 2020 | mean daptomycine plasma clearance (unit, liters per hour) |
| Evalutation of the adverse event due to daptomycin : daptomycine volume distribution | between 2010 and 2020 | mean daptomycine volume of distribution (unit, liters) |
Countries
France
Contacts
Primary ContactTristan Ferry, Md,PhD
Backup ContactEugenie Mabrut, CRA
Outcome results
None listed